VIA Pharmaceuticals, Inc. Announces First-in-Human Dosing of VIA-3196 for Treatment of Dyslipidemia
6/13/2011 9:01:13 AM
More...
|
VIA Pharmaceuticals, Inc. And Montreal Heart Institute Announce Publication of VIA-2291 5-Lipoxygenase Inhibitor Clinical Study Data in Circulation: Cardiovascular Imaging
5/20/2010 11:10:55 AM
More...
|
VIA Pharmaceuticals, Inc. Announces Strategic Restructuring; Reduces Workforce to Core R&D
4/1/2010 6:54:01 AM
More...
|
VIA Pharmaceuticals, Inc. Receives Delisting Notification From The Nasdaq Stock Market -- New York
12/30/2009 9:32:17 AM
More...
|
VIA Pharmaceuticals, Inc. Featured at American Heart Association Scientific Sessions 2009 VIA-3196 THR Beta Agonist Featured in Abstract Oral Session
11/4/2009 8:18:47 AM
More...
|
VIA Pharmaceuticals, Inc. Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
10/29/2009 8:51:05 AM
More...
|
VIA Pharmaceuticals, Inc. Receives Favorable Hearing Decision From The Nasdaq Stock Market -- New York
10/13/2009 9:03:38 AM
More...
|
VIA Pharmaceuticals, Inc. Receives Anticipated Deficiency Notice From The Nasdaq Stock Market -- New York
9/29/2009 9:25:30 AM
More...
|
VIA Pharmaceuticals, Inc. Receives Anticipated Notice From NASDAQ
7/19/2009 10:54:47 PM
More...
|
VIA Pharmaceuticals, Inc. Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
6/11/2009 11:03:42 AM
More...
|
|